We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BLENREP

News List

Blenrep granted CMA for relapsed or refractory multiple myeloma europeanpharmaceuticalreview
August 31, 2020
The European Commission granted the conditional marketing authorisation (CMA) based on data from a trial in which Blenrep achieved an overall response rate of 32 percent.
GSK bags EU approval for Blenrep pharmatimes
August 27, 2020
Hot on the heels of US approval GlaxoSmithKline has now also bagged a nod in Europe for Blenrep (belantamab mafodotin-blmf) as a treatment for patients with relapsed for refractory multiple myeloma (MM).
FDA Approves BLENREP americanpharmaceuticalreview
August 13, 2020
The U.S. Food and Drug Administration (FDA) approved BLENREP (belantamab mafodotin-blmf) for the treatment of adult patients with relapsed or refractory multiple myeloma ...
GSK gets USFDA approval for BLENREP to treat relapsed or refractory multiple myeloma expresspharma
August 07, 2020
BLENREP is the fifth major medicine approval for GSK in 2020.